Incidence of Severe Adverse Drug Reactions to Ultrasound Enhancement Agents in a Contemporary Echocardiography Practice.

OBJECTIVES: Prior data indicate very rare risk of serious adverse drug reaction (ADR) to ultrasound enhancement agents (UEA). We sought to evaluate the frequency of ADR to UEA administration in contemporary practice. METHODS: We retrospectively reviewed 4 U.S. Health Systems to characterize frequency and severity of ADR to UEA. ADR were considered severe when cardiopulmonary involvement was present and critical when there was loss of consciousness, loss of pulse, or ST-segment elevation. Rates of isolated back pain and headache were derived from the Mayo Clinic (MC) Rochester stress echocardiography database where systematic prospective reporting of ADR was performed. RESULTS: Among 26,539 Definity and 11,579 Lumason administrations in the MC Rochester stress echocardiography database, isolated back pain or headache were more frequent with Definity (0.49% vs 0.04%, p<0.0001) but less common with Definity infusion versus bolus (0.08% vs 0.53%, p=0.007). Among all sites there were 201,834 Definity and 84,943 Lumason administrations. Severe and critical ADR were more frequent with Lumason than Definity (0.0848% versus 0.0114% and 0.0330% versus 0.0010%, respectively; p<0.001 for each). Among the 3 Health Systems with >2,000 Lumason administrations, the frequency of severe ADR with Lumason ranged from 0.0755% to 0.1093% and the frequency of critical ADR ranged from 0.0293% to 0.0525%. Severe ADR rates with Definity were stable over time but increased in more recent years with Lumason (p=0.02). Patients with ADR to Lumason since the beginning of 2021 were more likely to have received Covid-19 vaccination compared to matched controls (88% versus 75%; p=0.05) and more likely to have received Moderna than Pfizer-Biotech (71% vs 26%, p<0.001). CONCLUSIONS: Severe and critical ADR, while rare, were more frequent with Lumason and the frequency has increased in more recent years. Additional work is needed to better understand factors, including associations with recently developed mRNA vaccines, which may be contributing to the increased rates of ADR to UEA since 2021.